Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
PPP2R2A mutation
Cancer:
Prostate Cancer
Drug:
Lynparza (olaparib)
(
PARP inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: A2 - Guideline
Source:
NCCN
Published date:
05/21/2020
Excerpt:
...Patients with PPP2RA mutations in the profound trial experienced an unfavorable risk benefit profile. Therefore olaparib is not recommended in patients with PPP2RA mutations.
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login